Exploring the Potential Mechanism of Liupao Tea Using UPLC-Q-TOF/MS and Network Pharmacology.

Gastrointestinal motility disorder (GMD) is a common condition characterized by dysfunction or degeneration of the myenteric plexus in specific segments of the gastrointestinal tract. Liupao tea (LPT) is a post-fermented tea that is rich in various secondary metabolites and has demonstrated a range of pharmacological effects, including lipid-lowering properties, antioxidant activity, and modulation of the gut microbiota. However, the underlying mechanisms by which LPT improves GMD remain poorly understood. Blood was collected after gavage of LPT extract in SD rats. The active components in the aqueous extract of LPT and its serum were analyzed using ultra-high-performance liquid chromatography quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF/MS). The targets of LPT in the treatment of GMD were predicted by network pharmacology and molecular docking. 65 compounds were identified in the water extract of LPT, including flavonoids, phenolic acids, alkaloids, and amino acids. In rats treated with LPT, 14 prototype compounds and 6 metabolites were detected in serum. Network pharmacology and molecular docking analyses revealed 298 common targets between LPT and GMD, including IL-6, AKT1, and TP53. Functional enrichment analysis suggested that LPT may improve GMD through the regulation of immune, inflammatory, and cytokine signaling pathways. Molecular docking further indicated that the primary bioactive components of LPT exhibit a strong affinity for IL-6, AKT1, and TP53. These findings provide new insights into the bioactive components, molecular targets, and mechanisms of LPT, suggesting its potential as a therapeutic strategy for gastrointestinal motility disorders.